{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,21]],"date-time":"2026-06-21T04:12:30Z","timestamp":1782015150272,"version":"3.54.5"},"reference-count":46,"publisher":"Public Library of Science (PLoS)","issue":"2","license":[{"start":{"date-parts":[[2013,2,15]],"date-time":"2013-02-15T00:00:00Z","timestamp":1360886400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0056122","type":"journal-article","created":{"date-parts":[[2013,2,15]],"date-time":"2013-02-15T23:11:47Z","timestamp":1360969907000},"page":"e56122","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":17,"title":["Differential Effects of Drug Interventions and Dietary Lifestyle in Developing Type 2 Diabetes and Complications: A Systems Biology Analysis in LDLr\u2212\/\u2212 Mice"],"prefix":"10.1371","volume":"8","author":[{"given":"Marijana","family":"Radonjic","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter Y.","family":"Wielinga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzan","family":"Wopereis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Kelder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Varshna S.","family":"Goelela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Verschuren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Toet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wim","family":"van Duyvenvoorde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bianca","family":"van der Werff van der Vat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna H. M.","family":"Stroeve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Cnubben","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teake","family":"Kooistra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben","family":"van Ommen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Kleemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2013,2,15]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S0140-6736(11)60614-4","article-title":"Type 2 diabetes across generations: From pathophysiology to prevention and management","volume":"378(9786)","author":"CJ Nolan","year":"2011","journal-title":"Lancet"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.diabres.2011.10.029","article-title":"IDF diabetes atlas: Global estimates of the prevalence of diabetes for 2011 and 2030","volume":"94(3)","author":"DR Whiting","year":"2011","journal-title":"Diabetes Res Clin Pract"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.pharmthera.2011.04.001","article-title":"Cellular and cytokine-based inflammatory processes as novel therapeutic targets for the prevention and treatment of atherosclerosis","volume":"131(3)","author":"PJ Little","year":"2011","journal-title":"Pharmacol Ther"},{"key":"ref4","first-page":"2545","article-title":"Effects of intensive glucose lowering in type 2 diabetes","volume":"358(24)","year":"2008","journal-title":"N Engl J Med"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1007\/s00125-009-1470-0","article-title":"Intensive glucose control and macrovascular outcomes in type 2 diabetes","volume":"52(11)","author":"FM Turnbull","year":"2009","journal-title":"Diabetologia"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1007\/s00125-010-1864-z","article-title":"Intensified glucose lowering in type 2 diabetes: Time for a reappraisal","volume":"53(10)","author":"JS Yudkin","year":"2010","journal-title":"Diabetologia"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMcp1013127","article-title":"Clinical practice. glycemic management of type 2 diabetes mellitus","volume":"366(14)","author":"F Ismail-Beigi","year":"2012","journal-title":"N Engl J Med"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1186\/1752-0509-5-125","article-title":"A systems biology strategy for predicting similarities and differences of drug effects: Evidence for drug-specific modulation of inflammation in atherosclerosis","volume":"5","author":"R Kleemann","year":"2011","journal-title":"BMC Syst Biol"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/ni.2001","article-title":"The immune system in atherosclerosis","volume":"12(3)","author":"GK Hansson","year":"2011","journal-title":"Nat Immunol"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"S52","DOI":"10.1038\/ijo.2008.238","article-title":"Inflammation and endoplasmic reticulum stress in obesity and diabetes","volume":"32","author":"GS Hotamisligil","year":"2008","journal-title":"Int J Obes (Lond)"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"e18432","DOI":"10.1371\/journal.pone.0018432","article-title":"Beneficial effects of alternate dietary regimen on liver inflammation, atherosclerosis and renal activation","volume":"6(3)","author":"PY Wielinga","year":"2011","journal-title":"PLoS One"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1210\/jcem.85.7.6661","article-title":"Quantitative insulin sensitivity check index: A simple, accurate method for assessing insulin sensitivity in humans","volume":"85(7)","author":"A Katz","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.1161\/01.ATV.0000238348.05028.14","article-title":"Fenofibrate reduces atherogenesis in ApoE*3Leiden mice: Evidence for multiple antiatherogenic effects besides lowering plasma cholesterol","volume":"26(10)","author":"T Kooistra","year":"2006","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"e6646","DOI":"10.1371\/journal.pone.0006646","article-title":"Genome-wide mRNA expression analysis of hepatic adaptation to high-fat diets reveals switch from an inflammatory to steatotic transcriptional program","volume":"4(8)","author":"M Radonjic","year":"2009","journal-title":"PLoS One"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1093\/bioinformatics\/btn224","article-title":"Lumi: A pipeline for processing illumina microarray","volume":"24(13)","author":"P Du","year":"2008","journal-title":"Bioinformatics"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"Article3","DOI":"10.2202\/1544-6115.1027","article-title":"Linear models and empirical bayes methods for assessing differential expression in microarray experiments","volume":"3","author":"GK Smyth","year":"2004","journal-title":"Stat Appl Genet Mol Biol"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"P3","DOI":"10.1186\/gb-2003-4-5-p3","article-title":"DAVID: Database for annotation, visualization, and integrated discovery","volume":"4(5)","author":"G Dennis Jr","year":"2003","journal-title":"Genome Biol"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1038\/ng0506-500","article-title":"GenePattern 2.0","volume":"38(5)","author":"M Reich","year":"2006","journal-title":"Nat Genet"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s11306-010-0254-3","article-title":"Quantitative metabolomics based on gas chromatography mass spectrometry: Status and perspectives","volume":"7(3)","author":"MM Koek","year":"2011","journal-title":"Metabolomics"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"e4525","DOI":"10.1371\/journal.pone.0004525","article-title":"Metabolic profiling of the response to an oral glucose tolerance test detects subtle metabolic changes","volume":"4(2)","author":"S Wopereis","year":"2009","journal-title":"PLoS One"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1007\/s11306-012-0421-9","article-title":"Fish oil and inflammatory status alter the n-3 to n-6 balance of the endocannabinoid and oxylipin metabolomes in mouse plasma and tissue","volume":"8(6)","author":"MG Balvers","year":"2012","journal-title":"Metabolomics"},{"key":"ref22","first-page":"837","article-title":"Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK prospective diabetes study (UKPDS) group","volume":"352(9131)","year":"1998","journal-title":"Lancet"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s11886-011-0238-6","article-title":"Does aggressive glycemic control benefit macrovascular and microvascular disease in type 2 diabetes? insights from ACCORD, ADVANCE, and VADT","volume":"14(1)","author":"T Terry","year":"2012","journal-title":"Curr Cardiol Rep"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1016\/S0140-6736(10)61112-9","article-title":"Intensified glucose control in type 2 diabetes\u2013whose agenda?","volume":"377(9773)","author":"JS Yudkin","year":"2011","journal-title":"Lancet"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"385","DOI":"10.2165\/00003495-200565030-00005","article-title":"Oral antidiabetic agents: Current role in type 2 diabetes mellitus","volume":"65(3)","author":"AJ Krentz","year":"2005","journal-title":"Drugs"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1056\/NEJMoa066224","article-title":"Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy","volume":"355(23)","author":"SE Kahn","year":"2006","journal-title":"N Engl J Med"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1056\/NEJMe0804182","article-title":"Intensive glycemic control in the ACCORD and ADVANCE trials","volume":"358(24)","author":"RG Dluhy","year":"2008","journal-title":"N Engl J Med"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.2337\/diabetes.54.7.2206","article-title":"Rosiglitazone improves glomerular hyperfiltration, renal endothelial dysfunction, and microalbuminuria of incipient diabetic nephropathy in patients","volume":"54(7)","author":"F Pistrosch","year":"2005","journal-title":"Diabetes"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1053\/j.ajkd.2004.11.004","article-title":"Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: Results from the diabetes atherosclerosis intervention study (DAIS)","volume":"45(3)","author":"JC Ansquer","year":"2005","journal-title":"Am J Kidney Dis"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1111\/j.1368-5031.2006.00882.x","article-title":"FIELDS of dreams, fields of tears: A perspective on the fibrate trials","volume":"60(4)","author":"AS Wierzbicki","year":"2006","journal-title":"Int J Clin Pract"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"e206","DOI":"10.1371\/journal.pmed.0050206","article-title":"Chronic antidiabetic sulfonylureas in vivo: Reversible effects on mouse pancreatic beta-cells","volume":"5(10)","author":"MS Remedi","year":"2008","journal-title":"PLoS Med"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1592\/phco.27.8.1102","article-title":"Loss of glycemic control in patients with type 2 diabetes mellitus who were receiving initial metformin, sulfonylurea, or thiazolidinedione monotherapy","volume":"27(8)","author":"AA Riedel","year":"2007","journal-title":"Pharmacotherapy"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"124","DOI":"10.2174\/187152512800388948","article-title":"PPAR- gamma agonist in treatment of diabetes: Cardiovascular safety considerations","volume":"10(2)","author":"A Abbas","year":"2012","journal-title":"Cardiovasc Hematol Agents Med Chem"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1517\/14740338.2011.534982","article-title":"The safety of thiazolidinediones","volume":"10(3)","author":"KG Tolman","year":"2011","journal-title":"Expert Opin Drug Saf"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.amjmed.2011.08.025","article-title":"The cardiovascular effects of peroxisome proliferator-activated receptor agonists","volume":"125(2)","author":"SN Friedland","year":"2012","journal-title":"Am J Med"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1002\/hep.23941","article-title":"Rosiglitazone attenuates age- and diet-associated nonalcoholic steatohepatitis in male low-density lipoprotein receptor knockout mice","volume":"52(6)","author":"AA Gupte","year":"2010","journal-title":"Hepatology"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1194\/jlr.M800374-JLR200","article-title":"LXR agonist suppresses atherosclerotic lesion growth and promotes lesion regression in apoE*3Leiden mice: Time course and mechanisms","volume":"50(2)","author":"L Verschuren","year":"2009","journal-title":"J Lipid Res"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/S0014-5793(02)03578-0","article-title":"T-0901317, a synthetic liver X receptor ligand, inhibits development of atherosclerosis in LDL receptor-deficient mice","volume":"536(1\u20133)","author":"N Terasaka","year":"2003","journal-title":"FEBS Lett"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.atherosclerosis.2009.07.016","article-title":"Differential effects of activation of liver X receptor on plasma lipid homeostasis in wild-type and lipoprotein clearance-deficient mice","volume":"208(1)","author":"D Peng","year":"2010","journal-title":"Atherosclerosis"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.atherosclerosis.2008.05.058","article-title":"Differential anti-atherosclerotic effects in the innominate artery and aortic sinus by the liver X receptor agonist T0901317","volume":"203(1)","author":"D Peng","year":"2009","journal-title":"Atherosclerosis"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S0021-9150(98)00263-9","article-title":"Progression and regression of atherosclerosis in APOE3-leiden transgenic mice: An immunohistochemical study","volume":"143(1)","author":"MJ Gijbels","year":"1999","journal-title":"Atherosclerosis"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.1172\/JCI57275","article-title":"Antagonism of miR-33 in mice promotes reverse cholesterol transport and regression of atherosclerosis","volume":"121(7)","author":"KJ Rayner","year":"2011","journal-title":"J Clin Invest"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"726","DOI":"10.2337\/dc08-0494","article-title":"Effect of progression from impaired glucose tolerance to diabetes on cardiovascular risk factors and its amelioration by lifestyle and metformin intervention: The diabetes prevention program randomized trial by the diabetes prevention program research group","volume":"32(4)","author":"RB Goldberg","year":"2009","journal-title":"Diabetes Care"},{"key":"ref44","doi-asserted-by":"crossref","unstructured":"Dunkley AJ, Charles K, Gray LJ, Camosso-Stefinovic J, Davies MJ, <etal>et al<\/etal>.. (2012) Effectiveness of interventions for reducing diabetes and cardiovascular disease risk in people with metabolic syndrome: Systematic review and mixed treatment comparison meta-analysis. Diabetes Obes Metab.","DOI":"10.1111\/j.1463-1326.2012.01571.x"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/nrd2894","article-title":"Advancing drug therapy of the metabolic syndrome","volume":"8(5)","author":"SM Grundy","year":"2009","journal-title":"Nat Rev Drug Discov"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1111\/j.1463-1326.2010.01282.x","article-title":"Restoring endoplasmic reticulum function by chemical chaperones: An emerging therapeutic approach for metabolic diseases","volume":"12","author":"F Engin","year":"2010","journal-title":"Diabetes Obes Metab"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0056122","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,9]],"date-time":"2019-07-09T20:22:03Z","timestamp":1562703723000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0056122"}},"subtitle":[],"editor":[{"given":"Massimo","family":"Federici","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2013,2,15]]},"references-count":46,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2013,2,15]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0056122","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,2,15]]}}}